Search company, investor...

NovImmune - emapalumab Unit


Acquired Unit | Acquired

About NovImmune - emapalumab Unit

NovImmune is a biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

Headquarters Location

14 Chemin des Aulx Plan-Les-Ouates

Geneva, CH-1228,


+41 22 839 71 41



NovImmune - emapalumab Unit Frequently Asked Questions (FAQ)

  • Where is NovImmune - emapalumab Unit's headquarters?

    NovImmune - emapalumab Unit's headquarters is located at 14 Chemin des Aulx, Geneva.

  • What is NovImmune - emapalumab Unit's latest funding round?

    NovImmune - emapalumab Unit's latest funding round is Acquired Unit.

  • Who are the investors of NovImmune - emapalumab Unit?

    Investors of NovImmune - emapalumab Unit include Sobi.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.